


## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1045929/publications.pdf Version: 2024-02-01



ΥΠΕ ///Π

#	Article	IF	CITATIONS
1	Discovery of Clinical Candidate (5-(3-(4-Chlorophenoxy)prop-1-yn-1-yl)-3-hydroxypicolinoyl)glycine, an Orally Bioavailable Prolyl Hydroxylase Inhibitor for the Treatment of Anemia. Journal of Medicinal Chemistry, 2020, 63, 10045-10060.	6.4	16
2	Click Chemistry-Based Discovery of [3-Hydroxy-5-(1 <i>H</i> -1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia. Journal of Medicinal Chemistry, 2018, 61, 5332-5349.	6.4	35
3	Application of in-vitro screening methods on hypoxia inducible factor prolyl hydroxylase inhibitors. Bioorganic and Medicinal Chemistry, 2017, 25, 3891-3899.	3.0	7
4	Small-molecule inhibitors of HIF-PHD2: a valid strategy to renal anemia treatment in clinical therapy. MedChemComm, 2016, 7, 1271-1284.	3.4	11
5	An improved and scalable synthesis of N-(5-(4-cyanophenyl)-3-hydroxypicolinoyl)glycine, a promising PHD2 inhibitor for the treatment of anemia. Tetrahedron Letters, 2015, 56, 5017-5019.	1.4	5